PBAC

Analysis and Comment (5)

87ssgs32-1366688517
We need a more rational debate about how and where we spend our finite health budget. Image from shutterstock.com

Explainer: what is health rationing?

By Anthony Scott, University of Melbourne

HEALTH RATIONING – a series which examines Australia’s rising health costs and the tough decisions governments must make to rein them it. Any mention of the “R” word in health care immediately brings…
Rmd7xfx4-1353478177
The biggest delay is arguably at the stage where sponsors can exert the most control over timing. Chris Kelly

Why medicines take so much time to get listed on the PBS

By Alison Pearce, University of Technology, Sydney

The Australian government introduced a controversial delay to the approval process for subsidised medicines last year, in an attempt to cut costs. We decided to examine the timelines of the approval process…
6213018330_2ace067465_b
Dabigatran’s manufacturer didn’t provide PBAC with data comparing its effectiveness to the most inexpensive medication treating the same conditions. Harveyben

The tricks companies use to get over-priced drugs on the PBS

By Thomas Faunce

Boehringer Ingelheim, manufacturer of the expensive anti-clotting drug dabigatran, has initiated a lobbying campaign to get it listed on the Pharmaceutical Benefits Scheme (PBS). The company’s efforts…
Assorted_pharmaceuticals_by_ladyofprocrastination
Uncertainty about how drugs will be listed on the PBS has patient groups, health professionals and the pharmaceutical industry worried. LadyofProcrastination/Wikimedia Commons

New PBS listing rule spooks pharma, doctors and patients

By Glenn Salkeld

Any parent who watches kids' weekend footy knows that if the ref misses a breach of the rules, merry hell breaks loose. But referees are human and sometimes make errors. We forgive the odd one pretty…

Participants (14)